Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient
- 30 July 2021
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 99, 108012
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Dose Adjustment Strategy of Cyclosporine A in Renal Transplant Patients: Evaluation of Anthropometric Parameters for Dose Adjustment and C0 vs. C2 Monitoring in Japan, 2001-2010International Journal of Medical Sciences, 2013
- Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In VitroDrug Metabolism and Disposition, 2012
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJAMA, 2011
- Characteristics of Thoracic Malignancies That Occur After Solid-Organ TransplantationJournal of Thoracic Oncology, 2010
- Malignancy after renal transplantation: the role of immunosuppressionNature Reviews Nephrology, 2010
- Cyclosporine Lowering With Everolimus or Mycophenolate to Preserve Renal Function in Heart Recipients: A Randomized StudyTransplantation, 2010
- Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted TherapyClinical Cancer Research, 2009
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Immunosuppressive Therapy and Malignancy in Organ Transplant RecipientsDrugs, 2007
- THE ROLE OF CYCLOSPORINE DOSAGE AND PLASMA LEVELS IN EFFICACY AND TOXICITY IN BONE MARROW TRANSPLANT RECIPIENTSTransplantation, 1987